Document Detail


Exercise training ameliorates the effects of rosiglitazone on traditional and novel cardiovascular risk factors in patients with type 2 diabetes mellitus.
MedLine Citation:
PMID:  19922961     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of the study was to investigate the effects of rosiglitazone and/or exercise training on novel cardiovascular risk factors in patients with type 2 diabetes mellitus. One hundred overweight/obese type 2 diabetes mellitus patients, with inadequate glycemic control (hemoglobin A(1c) >7%) despite combined treatment with gliclazide plus metformin, were randomized using a 2 x 2 factorial design to 4 equivalent (n = 25) groups, as follows: (1) CO: maintenance of habitual activities, (2) RSG: add-on therapy with rosiglitazone (8 mg/d), (3) EX: adjunctive exercise training, and (4) RSG + EX: supplementary administration of rosiglitazone (8 mg/d) plus exercise training. No participant had diabetic vascular complications or was receiving lipid-lowering therapy. Anthropometric parameters, cardiorespiratory capacity, glycemic and lipid profile, apolipoprotein (apo) A-I, apo B, interleukin (IL)-10, IL-18, insulin resistance, and blood pressure were measured before and after 12 months of intervention (P < .05). Both RSG and EX groups significantly reduced glycemic indexes, insulin resistance, blood pressure, and IL-18, whereas they significantly increased high-density lipoprotein, cardiorespiratory capacity, and IL-10, compared with CO group (P < .05). Besides this, exercise-treated patients conferred a remarkable down-regulation in the rest of lipid parameters (total cholesterol, low-density lipoprotein cholesterol, triglycerides, apo B) and body fat content (P < .05) in comparison with CO group. On the other hand, RSG group rather than CO group considerably increased apo A-I levels and body mass index (P < .05). Notably, the combined treatment group yielded pronounced beneficial changes in glycemic indexes, lipid profile, insulin resistance, blood pressure, IL-10, IL-18, apo A-I, and apo B (vs CO group, P < .05). Furthermore, the addition of exercise to rosiglitazone treatment counteracted the drug-related negative effects on body weight, low-density lipoprotein, and total cholesterol. Rosiglitazone plus exercise training elicited additive effects on body composition, glycemic control, and traditional and novel cardiovascular risk factors in type 2 diabetes mellitus patients, indicating complementary effects.
Authors:
Nikolaos P E Kadoglou; Fotios Iliadis; Nikolaos Sailer; Zoi Athanasiadou; Ioulia Vitta; Alikistis Kapelouzou; Panayotis E Karayannacos; Christos D Liapis; Miltiadis Alevizos; Nikoletta Angelopoulou; Ioannis S Vrabas
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2009-11-18
Journal Detail:
Title:  Metabolism: clinical and experimental     Volume:  59     ISSN:  1532-8600     ISO Abbreviation:  Metab. Clin. Exp.     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-03-22     Completed Date:  2010-04-07     Revised Date:  2010-06-07    
Medline Journal Info:
Nlm Unique ID:  0375267     Medline TA:  Metabolism     Country:  United States    
Other Details:
Languages:  eng     Pagination:  599-607     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier Inc. All rights reserved.
Affiliation:
1st Department of Internal Medicine, "Hippokratio" General Hospital of Thessaloniki, Greece. nikoskad@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Body Composition
C-Reactive Protein / analysis
Cardiovascular Diseases / prevention & control*
Diabetes Mellitus, Type 2 / complications*
Exercise*
Female
Hemoglobin A, Glycosylated / analysis
Humans
Hypoglycemic Agents / pharmacology*
Insulin Resistance
Lipoproteins, LDL / blood
Male
Middle Aged
Risk Factors
Thiazolidinediones / pharmacology*
Chemical
Reg. No./Substance:
0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/Lipoproteins, LDL; 0/Thiazolidinediones; 0/hemoglobin A1c protein, human; 122320-73-4/rosiglitazone; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Growth and maturation of the cases of congenital hypothyroidism detected by the neonatal screening p...
Next Document:  Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal...